S Kayaniyil1, M Hurry2, J Wilson1, P Wheatley-Price3, B Melosky4, J Rothenstein5, V Cohen6, C Koch2, J Zhang7, K Osenenko1, G Liu8. 1. icon Health Economics and Epidemiology, Vancouver, BC. 2. Novartis Pharmaceuticals Canada, Dorval, QC. 3. Ottawa Hospital Research Institute, and Department of Medicine, University of Ottawa, Ottawa, ON. 4. Division of Medical Oncology, University of British Columbia, Vancouver, BC. 5. rsm Durham Regional Cancer Centre, Lakeridge Health, Oshawa, ON. 6. Department of Oncology, Jewish General Hospital, Montreal, QC. 7. Novartis Pharmaceutical Corporation, East Hanover, NJ, U.S.A. 8. Princess Margaret Cancer Centre, Toronto, ON.
Abstract
BACKGROUND: Crizotinib was the first agent approved for the treatment of anaplastic lymphoma kinase (ALK)-positive (+) non-small-cell lung cancer (nsclc), followed by ceritinib. However, patients eventually progress or develop resistance to crizotinib. With limited real-world data available, the objective of the present work was to evaluate treatment patterns and survival after crizotinib in patients with locally advanced or metastatic ALK+ nsclc in Canada. METHODS: In this retrospective study at 6 oncology centres across Canada, medical records of patients with locally advanced or metastatic ALK+ nsclc were reviewed. Demographic and clinical characteristics, treatments, and outcomes data were abstracted. Analyses focused on patients who discontinued crizotinib treatment. RESULTS: Of the 97 patients included, 9 were crizotinib-naïve, and 39 were still receiving crizotinib at study end. The 49 patients who discontinued crizotinib treatment were included in the analysis. Of those 49 patients, 43% received ceritinib at any time, 20% subsequently received systemic chemotherapy only (but never ceritinib), and 37% received no further treatment or died before receiving additional treatment. Median overall survival from crizotinib discontinuation was shorter in patients who did not receive ceritinib than in those who received ceritinib (1.7 months vs. 20.4 months, p < 0.001). In a multivariable analysis, factors associated with poorer survival included lack of additional therapies (particularly ceritinib), male sex, and younger age, but not smoking status; patients of Asian ethnicity showed a nonsignificant trend toward improved survival. CONCLUSIONS: A substantial proportion of patients with ALK+ nsclc received no further treatment or died before receiving additional treatment after crizotinib. Treatment with systemic agents was associated with improved survival, with ceritinib use being associated with the longest survival.
BACKGROUND:Crizotinib was the first agent approved for the treatment of anaplastic lymphoma kinase (ALK)-positive (+) non-small-cell lung cancer (nsclc), followed by ceritinib. However, patients eventually progress or develop resistance to crizotinib. With limited real-world data available, the objective of the present work was to evaluate treatment patterns and survival after crizotinib in patients with locally advanced or metastatic ALK+ nsclc in Canada. METHODS: In this retrospective study at 6 oncology centres across Canada, medical records of patients with locally advanced or metastatic ALK+ nsclc were reviewed. Demographic and clinical characteristics, treatments, and outcomes data were abstracted. Analyses focused on patients who discontinued crizotinib treatment. RESULTS: Of the 97 patients included, 9 were crizotinib-naïve, and 39 were still receiving crizotinib at study end. The 49 patients who discontinued crizotinib treatment were included in the analysis. Of those 49 patients, 43% received ceritinib at any time, 20% subsequently received systemic chemotherapy only (but never ceritinib), and 37% received no further treatment or died before receiving additional treatment. Median overall survival from crizotinib discontinuation was shorter in patients who did not receive ceritinib than in those who received ceritinib (1.7 months vs. 20.4 months, p < 0.001). In a multivariable analysis, factors associated with poorer survival included lack of additional therapies (particularly ceritinib), male sex, and younger age, but not smoking status; patients of Asian ethnicity showed a nonsignificant trend toward improved survival. CONCLUSIONS: A substantial proportion of patients with ALK+ nsclc received no further treatment or died before receiving additional treatment after crizotinib. Treatment with systemic agents was associated with improved survival, with ceritinib use being associated with the longest survival.
Authors: Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge Journal: Lancet Oncol Date: 2011-09-18 Impact factor: 41.316
Authors: A Guérin; M Sasane; H Wakelee; J Zhang; K Culver; K Dea; R Nitulescu; P Galebach; A R Macalalad Journal: Curr Med Res Opin Date: 2015-06-29 Impact factor: 2.580
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245
Authors: Jose M Pacheco; Dexiang Gao; Derek Smith; Thomas Purcell; Mark Hancock; Paul Bunn; Tyler Robin; Arthur Liu; Sana Karam; Laurie Gaspar; Brian Kavanagh; Chad Rusthoven; Dara Aisner; Robert Doebele; D Ross Camidge Journal: J Thorac Oncol Date: 2018-12-30 Impact factor: 15.609
Authors: Amanda J W Gibson; Adrian Box; Michelle L Dean; Anifat A Elegbede; Desiree Hao; Randeep Sangha; D Gwyn Bebb Journal: JTO Clin Res Rep Date: 2021-03-01
Authors: Wei Fang Dai; Claire de Oliveira; Scott Blommaert; Reka E Pataky; David Tran; Zeb Aurangzeb; Cynthia Kendell; Chris Folkins; Chandy Somayaji; Jeff Dowden; Winson Cheung; Erin Strumpf; Jaclyn M Beca; Carol McClure; Robin Urquhart; James Ted McDonald; Riaz Alvi; Donna Turner; Stuart Peacock; Avram Denburg; Rebecca E Mercer; Caroline Muñoz; Ambica Parmar; Mina Tadrous; Pam Takhar; Kelvin K W Chan Journal: Curr Oncol Date: 2022-03-17 Impact factor: 3.677